Medicare 2026

Multi-Cancer Screening Tests and Medicare: What the 2026 Law Allows Starting in 2029

A new federal law opens the door for Medicare to cover a next generation of cancer screening — a single blood test designed to look for signs of many cancers at once. The coverage does not begin right away, and it comes with specific rules. Here is a plain-English look at what Congress wrote into law and what it will mean for people with Medicare.

What the law actually does

Section 6221 of the Consolidated Appropriations Act, 2026 (Public Law 119-75), signed on February 3, 2026, adds multi-cancer early detection screening tests to the list of services Medicare Part B can cover. These tests look for multiple types of cancer across multiple organ sites at the same time. The coverage applies to tests furnished on or after January 1, 2029, provided they meet the law's conditions.

For a test to qualify, three things must be true:

1. It must be cleared or approved by the Food and Drug Administration. 2. It must be a genomic sequencing blood test that analyzes cell-free nucleic acids — or another sample-based test that the Department of Health and Human Services finds gives comparable results. 3. HHS must determine, through Medicare's national coverage determination process, that the test is reasonable and necessary and appropriate for people with Medicare.

In other words, the law creates the authority, but the Food and Drug Administration and HHS still have to do their reviews before any specific test is covered.

Who can and cannot get a covered test

The law sets some clear limits on who Medicare can pay for:

• No one under age 50.
• No one who had a covered multi-cancer screening test in the previous 11 months.
• In 2029, no one who is 65 or older as of January 1, 2029.

That upper age cutoff rises by one year each year. Because the cutoff and each person's age both go up by one year every year, someone who is already 65 or older on January 1, 2029 will stay at or above the cutoff in every later year, while someone who is younger than 65 on that date will stay below it.

These age and frequency limits can eventually fall away. Once the U.S. Preventive Services Task Force recommends a specific test with a grade of A or B and Medicare covers it as an additional preventive service, those limits stop applying to that test.

How Medicare will pay for it

Through 2030, Medicare's payment for a multi-cancer screening test will equal the payment amount in effect on the date of enactment for a multi-target stool DNA colorectal cancer screening test. Beginning January 1, 2031, the payment will be the lesser of that amount or the amount set under Medicare's clinical laboratory payment rules.

Importantly, the law protects your existing screening benefits. Having a multi-cancer screening test does not affect Part B coverage of other cancer screening tests — such as those for breast, cervical, colorectal, lung or prostate cancer — and having one of those screenings does not affect coverage of a multi-cancer test.

What this means in practical terms

The law takes effect in 2029, so there is nothing to sign up for today. When the time comes, this will be a Part B benefit, meaning it will flow through either Original Medicare or a Medicare Advantage plan (which must cover what Part B covers). Whether you pay anything out of pocket, and how the test is ordered, will depend on how FDA-approved tests come to market and how Medicare's coverage decision is written.

While you are thinking ahead: a few 2027 basics

The Part D out-of-pocket cap rises to $2,400 in 2027 (up from $2,100 in 2026). The most a Part D plan can charge as a deductible in 2027 is $700. The Part D base beneficiary premium for 2027 is $41.33 — a national figure used to calculate the late-enrollment penalty; actual plan premiums are set plan by plan. Social Security announced on October 14, 2026 a 3.6 percent cost-of-living adjustment for benefits payable beginning January 2027.

The 2027 Part B standard premium and deductible, and the 2027 IRMAA income brackets, have not yet been announced. CMS typically releases those figures in the fall.

Annual Enrollment runs October 15 – December 7, 2026 for coverage that starts January 1, 2027. During that window you can switch between Original Medicare and Medicare Advantage, change Part D plans, or pick up Part D if you are eligible.

If you have Medicaid or Extra Help, you have a monthly Special Enrollment Period to move to Original Medicare with a stand-alone Part D plan or to switch stand-alone Part D plans. Full-benefit dual-eligible individuals may enroll in an integrated Dual Eligible Special Needs Plan (D-SNP) in any month.

Original Medicare + Medigap vs. Medicare Advantage: stay informed, decide for yourself

Both paths will cover any Part B benefit that becomes available, including a multi-cancer screening test once Medicare's coverage rules take effect. Original Medicare with a Medigap policy generally lets you see any provider nationwide who accepts Medicare, with a separate Part D plan for drugs; Medigap premiums are an added cost but can smooth out cost-sharing. Medicare Advantage bundles medical and often drug coverage, usually with network rules and plan-specific cost sharing, and may include extras. Weigh access, costs, and your own doctors and prescriptions — the right choice is personal.

Where to go for official information

For the most current rules, enrollment windows, and coverage details, visit Medicare.gov or call 1-800-MEDICARE (1-800-633-4227), TTY 1-877-486-2048, 24 hours a day, 7 days a week.